153 related articles for article (PubMed ID: 11464883)
1. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Fulda S; Fichtner I; Hero B; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
[TBL] [Abstract][Full Text] [Related]
2. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
3. Effect of amifostine on neuroblastoma during high dose chemotherapy: in vivo and in vitro investigations.
Renner S; Krümpelmann S; Bruchelt G; Wiesinger H; Niethammer D; Klingebiel T
Anticancer Res; 2000; 20(6B):4531-8. PubMed ID: 11205300
[TBL] [Abstract][Full Text] [Related]
4. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner I; Lemm M; Becker M; Berthold F
Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
[TBL] [Abstract][Full Text] [Related]
5. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
[TBL] [Abstract][Full Text] [Related]
7. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
Borsi JD; Csaki C; Ferencz T; Oster W
Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109
[TBL] [Abstract][Full Text] [Related]
8. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
9. Amifostine and chemotherapy-related thrombocytopenia.
Budd GT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma.
Fuchs J; Wenderoth M; von Schweinitz D; Haindl J; Leuschner I
Cancer; 1998 Dec; 83(11):2400-7. PubMed ID: 9840541
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Fouladi M; Stempak D; Gammon J; Klein J; Grant R; Greenberg ML; Koren G; Baruchel S
Cancer; 2001 Aug; 92(4):914-23. PubMed ID: 11550166
[TBL] [Abstract][Full Text] [Related]
12. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
13. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
[TBL] [Abstract][Full Text] [Related]
14. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
Budd GT; Ganapathi R; Bukowski RM; Murthy S
Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of spontaneous metastases formation by amifostine.
Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Johnson PW; Muers MF; Peake MD; Poulter KM; Gurney EM; Napp VV; Hepburn PM; Brown JM
Br J Cancer; 2001 Jan; 84(1):19-24. PubMed ID: 11139307
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green D; Bensely D; Schein P
Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
[TBL] [Abstract][Full Text] [Related]
19. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
20. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
